

# Gemini Stock Analysis Report

---

Okay, I will analyze the report for Lupin.NS and provide a positional trading recommendation.

## Step 1: Audit the Data

### Data Present:

- 3-Year Daily Price Chart
- Long-term (4 Years) and Short-term (6 Quarters) Fundamental Analysis
- Relative Strength Analysis (RS Ratios, RS Composite Score, Price Performance vs. Index)
- EMA Crossover Analysis (EMA 20, 50, 200)
- Bollinger Bands (20, 2) Analysis
- Supertrend Analysis
- MACD Analysis
- Volatility Squeeze Analysis
- RSI-Volume Divergence Analysis

### Data Missing:

- Weekly or Monthly Charts
- Detailed Volume Price Analysis (beyond what's provided in RSI-Volume Divergence)
- Broader Sector Analysis (e.g., performance of other pharma companies)
- News Catalysts

**Confidence Level:** Medium. The report provides a good breadth of technical and fundamental data, especially regarding the daily price action and trend indicators. However, the lack of weekly/monthly data and more detailed volume analysis limits the ability to confirm the intermediate-term trend with high confidence.

## Step 2: Analyze the Setup

### • Price Structure and Trend:

- The 3-year daily chart shows a clear uptrend, starting in early 2023 and continuing to the present.
- Recent price action suggests consolidation in the latter half of 2025. The stock traded in a trading range of INR 1900 - INR 2150.
- The price is currently above the 20, 50, and 200-day EMAs, indicating a bullish trend. A recent Golden Cross further supports this.

### • Momentum:

- The RSI is at 65.23, indicating positive momentum, though not yet in overbought territory.
- MACD is bullish and strengthening.
- Relative Strength (RS) ratios show that the stock is an emerging leader, outperforming its benchmark.

### • Confluence and Cautionary Notes:

- The fundamental analysis shows both long-term and short-term growth in revenue.
- However, the short-term ROE is declining.
- The volatility squeeze analysis indicates contracting volatility, which could precede a significant price move (in either direction).

## Step 3: Formulate the Recommendation

Based on the above analysis, the setup shows bullish signs, but caution is needed given the recent consolidation and volatility contraction.

# Gemini Stock Analysis Report

---

## Recommendation: No entry at current prices.

While the overall trend is up, the stock's consolidation phase and the volatility squeeze create uncertainty.

Premature entry carries increased risk.

## Conditional Plan:

- **Condition to Buy:** Breakout above the upper end of the consolidation range (INR 2150) AND a close above the upper Bollinger Band. This would confirm a resumption of the uptrend with renewed momentum.
- **Entry Price:** INR 2150 (upon closing above resistance)
- **Stop Loss:** INR 2030 (Just below 50 EMA and previous support)
- **Take Profit:** INR 2350 (Approx. 10% from entry, and at a potential resistance level)

## News & Analyst Targets

Okay, I will act as a stock research analyst and gather the latest information on Lupin (LUPIN) to answer your questions.

Here's the latest information on Lupin (LUPIN), gathered as of December 20, 2025:

### 1. Latest News for LUPIN This Week:

- **Licensing Agreement with Neopharmed:** Lupin signed an exclusive licensing agreement with Neopharmed Gentili S.p.A. for the gastroenterology brand Plasil in the Philippines and Brazil. This will expand Lupin's presence in these emerging markets and enhance its gastroenterology portfolio. (December 18, 2025)
- **Positive CHMP Opinion for Biosimilar Ranibizumab:** Lupin received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its biosimilar Ranibizumab. (December 17, 2025)
- **EIR from US FDA for Nagpur Facility:** Lupin received the Establishment Inspection Report (EIR) from the U.S. FDA for its injectables facility in Nagpur, India, with a 'Voluntary Action Indicated (VAI)' classification, following an inspection in September 2025. (December 16, 2025)
- **SBTi Validation for Emission Reduction Targets:** Lupin secured validation from the Science Based Targets initiative (SBTi) for its emission reduction targets. (December 16, 2025)
- **Strategic Alliance for Peptide Supply Chain:** Lupin Manufacturing Solutions and PolyPeptide announced a strategic alliance to scale the global peptide supply chain. (December 12, 2025)
- **Tentative Approval for Siponimod Tablets:** Lupin received tentative approval from the U.S. FDA for Siponimod Tablets. (December 5, 2025)
- **Q2 FY26 Results:** Lupin reported a strong Q2 FY26 with a 73% YoY surge in PAT to Rs 1,485 crore and a 24% YoY jump in revenue to Rs 6,831 crore. (Source: Economic Times, November 7, 2025)
- **ESG Score:** Lupin established a new global standard in sustainable pharma with an S&P Global ESG Score of 91. (Source: Economic Times)
- **Lupin Shares Allotment:** Lupin has allotted 36626 shares under ESOP. (Source: Economic Times, December 10, 2025)

### 2. Analyst Upgrades and Downgrades for LUPIN:

- **Jefferies Upgrade:** Jefferies upgraded Lupin from Hold to Buy with a price target of INR 2,250.00 (from INR 2,200.00).
- **HSBC Remains Buy:** HSBC analyst Damayanti Kerai raised the price target on Lupin to INR 2,340.00 (from INR 2,300.00) while maintaining a Buy rating.

### 3. Other News Impacting LUPIN:

# Gemini Stock Analysis Report

---

- **Mutual Fund Trimming:** Quant Mutual Fund scaled down its holdings in Lupin in November.
- **Technical Breakout:** Lupin Ltd, a pharma stock, has broken out of a 7-month consolidation, signaling a potential bull comeback. Experts suggest short-term traders with a high-risk profile can consider buying for a target of Rs 2,290 in the coming months, with a stop loss below Rs 1,940.

## 4. Analyst Price Targets for LUPIN:

Here's a summary of analyst price targets for Lupin:

Brokerage/Analyst	Rating	Price Target (INR)
Average	Strong Buy	2,309.00
High		2,600.00
Low		2,096.00
HSBC	Buy	2,340.00
Kotak Mahindra	Add (2)	2,200.00
Morgan Stanley	Equalweight	2,096.00
Jefferies	Buy (Upgrade)	2,250.00
Market Screener	OUTPERFORM	2,280.84

*Note:* Analyst ratings and price targets are subject to change.


# Stock Detailed Analysis Report

**LUPIN.NS**

Current Price: ₹2125.80

Generated: 2025-12-20 20:45

# LUPIN.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

# LUPIN.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	51.5/100
:	

## == RS RATIOS ==:

1M RS:	1.044 [Leader]
3M RS:	1.026 [Leader]
6M RS:	1.028 [Leader]
1Y RS:	1.011 [Leader]
:	


## == TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


## SIGNAL CRITERIA::

✓ Emerging RS:	1M (1.044) > 3M (1.026)
✗ Medium-term Lagging:	Not lagging
✗ Performance Improving:	Not improving


**Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA**  
**Classification: Emerging Leader**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**



**RS Composite Score Timeline**



## LUPIN.NS - EMA Crossover Summary

<b>EMA 20:</b>	2080.28
<b>EMA 50:</b>	2039.03
<b>EMA 200:</b>	1995.39
<b>Trend Status:</b>	<b>Strong Uptrend</b>
<b>Golden Cross Date:</b>	2025-11-18 00:00:00
<b>Golden Cross Price:</b>	2047.40

## LUPIN.NS EMA Crossover Analysis



## LUPIN.NS - Bollinger Bands Summary

<b>Current Price:</b>	2125.80
<b>Upper Band:</b>	2139.20
<b>Middle Band (SMA 20):</b>	2080.87
<b>Lower Band:</b>	2022.54
<b>%B:</b>	0.8851
<b>Band Width:</b>	0.0561
<b>Status:</b>	Upper Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Sell Signal at 2025-11-17 00:00:00</b>


## LUPIN.NS Bollinger Bands (20, 2) Analysis



## LUPIN.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	2028.97
Signal Identified On:	2025-11-12

### Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## LUPIN.NS - MACD Summary

<b>MACD Line:</b>	25.44
<b>Signal Line:</b>	23.98
<b>Histogram:</b>	1.46
<b>Trend:</b>	<b>Bullish</b>
<b>Momentum:</b>	<b>Strengthening</b>
<b>Signal:</b>	None

LUPIN.NS Price




LUPIN.NS MACD (12, 26, 9)



## LUPIN.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0561
<b>ATR:</b>	33.3428
<b>Total Signals:</b>	34
<b>Signal 1:</b>	ATR Contraction at 2025-12-15 00:00:00 (Price: 2092.60)
<b>Signal 2:</b>	ATR Contraction at 2025-12-16 00:00:00 (Price: 2090.60)
<b>Signal 3:</b>	ATR Contraction at 2025-12-17 00:00:00 (Price: 2113.10)
<b>Signal 4:</b>	ATR Contraction at 2025-12-18 00:00:00 (Price: 2119.10)
<b>Signal 5:</b>	ATR Contraction at 2025-12-19 00:00:00 (Price: 2125.80)

# LUPIN.NS - Volatility Squeeze Analysis



## LUPIN.NS - RSI-Volume Summary

<b>Current RSI:</b>	65.23
<b>Current Volume:</b>	595995
<b>Volume MA 20:</b>	936198
<b>Bullish Divergences:</b>	0
<b>Bearish Divergences:</b>	2
<b>Bearish Div 1:</b>	Date: 2024-03-05 00:00:00, Price: 1678.75
<b>Bearish Div 2:</b>	Date: 2025-04-28 00:00:00, Price: 2105.40

# LUPIN.NS RSI-Volume Divergence Analysis

